Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in persistent moderate to severe atopic dermatitis
NCT02465606Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2015
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Roche. Started Jul 2015; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02465606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465606.